Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.

Indicators

Markets:

News

Depo-Provera (DP) and generic equivalent (DMPA) investigated by Federman & Sherwood

By: Federman & Sherwood via GlobeNewswire

April 03, 2025 at 19:30 PM EDT

OKLAHOMA CITY, Okla., April 03, 2025 (GLOBE NEWSWIRE) -- Depo-Provera (DP) and generic equivalent (DMPA) investigated by Federman & Sherwood. Federman & Sherwood, a premier boutique class-action litigation law firm based in Oklahoma City and Dallas announced that it is investigating cases related to women’s use of Depo-Provera (DP) and its generic equivalent (DMPA). DP is used as an injectable birth control and to manage menstrual cycles. At high doses it can be used to treat certain types of cancer. Its use has been linked to possibly cause brain tumors including meningioma brain tumors. This new evidence is supporting lawsuits that seek to compensate women for medical monitoring and financial compensation. If you took or know someone who took Depo-Provera you should find out what your rights are to seek financial compensation.

Federman & Sherwood is committed to providing aggressive legal representation to recover financial compensation for women harmed by use of DP or its generic equivalent.

If you wish to discuss this action, obtain further information, and/or participate in this litigation, please contact Tashia Poore either by email at tdp@federmanlaw.com or visit our firm’s website www.federmanlaw.com.

Tashia Poore
FEDERMAN & SHERWOOD
(405) 235-1560

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security. All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.
Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.